PT Kalbe Farma Tbk

As of June 30, 2026, PT Kalbe Farma Tbk carries a market capitalization of 1.36B, placing it among publicly traded companies globally. Its enterprise value stands at 1.22B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

PT Kalbe Farma Tbk's next confirmed earnings release is scheduled for November 3, 2026.

As of June 30, 2026, PT Kalbe Farma Tbk has 45.25B shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, PT Kalbe Farma Tbk maintains a current ratio of 3.15, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026. Inventory turnover of 3.16 indicates how many times PT Kalbe Farma Tbk sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, PT Kalbe Farma Tbk recorded 39.66M in income tax expense.

As of the close on October 22, 2026, PT Kalbe Farma Tbk's stock has declined approximately 42.06% over the past 52 weeks. The 50-day moving average sits at 0.03, while the 200-day moving average is 0.04.

These figures cover the twelve months ended June 30, 2026.

As of June 30, 2026, PT Kalbe Farma Tbk holds 243.00M in cash and equivalents against 40.23M in total debt, resulting in a net debt position of -197.35M. Total book value stands at 1.19B, with working capital of 698.45M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, PT Kalbe Farma Tbk paid dividends of -NaN per share.

PT Kalbe Farma Tbk's most recent stock split took place on October 8, 2012 with a 1:5 split ratio.